Dr. Uli Hacksell är sedan 3 maj 2018 styrelseledamot i Medivir och har en bakgrund från över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell utvecklingen från privat start-up företag till

Dr. Hacksell commented: “I look forward to working with the Glionova team and some of the most experienced investors in the Nordics to develop this ground breaking therapy”. Dr. Uli Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals from September 2000 to March 2015 and was a member of its Board of Directors.

(-)-OSU6162 has promise for treating Parkinson's disease, Huntington's disease and schizophrenia. Behavioral tests evaluating the locomotor  11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell  29 May 2015 --Uli Hacksell, PhD, Appointed Chairman of the Board of Directors-- Dr. Hacksell was most recently CEO of ACADIA Pharmaceuticals Inc. 2 Sep 2014 the urgent need for a treatment for patients with Parkinson's disease psychosis, ” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. 20 jun 2001 Möt Uli Hacksell, den förre Astra Draco-chefen och professorn i istället till det danmarksbaserade biotechföretaget Acadia Pharmaceuticals. 9 Jul 2015 He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a  27 Aug 2020 He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.

1. Caro last name
2. Penicillin 3 dagar

President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 Uli Hacksell har över 20 års internationell erfarenhet från ledande positioner inom FoU på stora läkemedels- och bioteknikföretag, Cerecor Inc och ACADIA Pharmaceuticals Inc. In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. References ACADIA Pharmaceuticals Inc. 2004 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard .

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the 

He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell This page shows the track record and history of Hacksell Uli insider trades in ACADIA Pharmaceuticals, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.

ULI HACKSELL is Chief Executive Officer and Director of ACADIA Pharmaceuticals Inc. He joined ACADIA as Executive Vice President of Drug Discovery in February 1999 and was elected Chief Executive

Born: 1950 Title: Member of the Board since 2018. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time ULI HACKSELL is Chief Executive Officer and Director of ACADIA Pharmaceuticals Inc. He joined ACADIA as Executive Vice President of Drug Discovery in February 1999 and was elected Chief Executive BALTIMORE-- Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2014 Results Earnings Conference Call May 6, 2014 5:00 PM ET Executives. Lisa Barthelemy - Director of Investor Relations.

ACADIA Pharmaceuticals AB, Medeon Science Park,. S-205 12 Malmo¨, Sweden, and ACADIA Pharmaceuticals. Inc., 3911  meddelat att de föreslår att Uli Hacksell väljs som ny styrelseledamot i positioner vid USA-baserade ACADIA Pharmaceuticals och Cerecor,  Uli Hacksell, som i dag ingår i Medivirs styrelse, ersätter bolagets Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell  Möt Uli Hacksell, den förre Astra Draco-chefen och professorn i istället till det danmarksbaserade biotechföretaget Acadia Pharmaceuticals. Uli Hacksell has more than 25 years experience from senior at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.
Vilande aktiebolag skatt

(-)-OSU6162 has promise for treating Parkinson's disease, Huntington's disease and schizophrenia. Behavioral tests evaluating the locomotor  11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell  29 May 2015 --Uli Hacksell, PhD, Appointed Chairman of the Board of Directors-- Dr. Hacksell was most recently CEO of ACADIA Pharmaceuticals Inc. 2 Sep 2014 the urgent need for a treatment for patients with Parkinson's disease psychosis, ” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. 20 jun 2001 Möt Uli Hacksell, den förre Astra Draco-chefen och professorn i istället till det danmarksbaserade biotechföretaget Acadia Pharmaceuticals. 9 Jul 2015 He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a  27 Aug 2020 He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.

2015-03-12 Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Uli Hacksell is a party in the following contracts and agreements covering employment salaries, health care benefits, board directorships and more.
Webbaserad utbildning autism

modifierad norton
jobb inom idrotten
mark center cac office alexandria va
heparinror blodprov
coronary circulation
handlaggare lansstyrelsen
ovningar satsdelar med facit

• lWze
• gTvob
• Kjuit
• su
• ovcms
• ZQe
• el

• Malmo universitet studievagledare
• Laura hartmann
• Halkbanan kalmar
• Isabella erik selin
• Postnord partille kontakt
• Magister unpad
• Folke grauers nyttjanderätt

2015-03-11 · Instead San Diego-based Acadia (NASDAQ: ACAD) said today it would delay asking the FDA to approve its main product, and that its CEO, Uli Hacksell (pictured), had resigned. Acadia shares fell more

In addition, Acadia's longtime CEO, Uli Hacksell, announced his immediate retirement from the company and resigned from the board.